1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Takeda Feels Need For Speed In Approaching Shire Integration

 
• By Ian Haydock

Takeda has fleshed out several aspects of its planned acquisition of Shire, emphasizing the need for speed and decisiveness if the integration is to be successful, although investors may need more reassurance ahead of required shareholder approval. 

map
TAKEDA FLESHES OUT SHIRE PROPOSAL BUT MORE CONVINCING NEEDED? • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd.'s $62bn planned acquisition of Shire PLC may be moving ahead - pending shareholder approval - but in many ways the hard work is just beginning, even after a protracted pursuit that saw the Japanese firm raise its bid five times before final success.

While the acquisition of a late-stage pipeline and products in new niche areas are being seen as the main benefits by analysts in Japan, despite extensive elucidation of the key benefits of the deal by management, many investors in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.